Investors Anxiously Await These 5 Healhcare Earnings Reports on Deck

Aetna, Inc. (NYSE:AET) will unveil its latest earnings on Thursday, April 26, 2012. The average estimate of analysts is for net income of $1.40 per share, a decline of 2.1% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.38. Between one and three months ago, the average estimate moved up. It has been unchanged at $1.40 during the last month. Analysts are projecting profit to rise by 0.4% compared to last year’s $5.15.

Last quarter, the company saw profit of 97 cents per share versus a mean estimate of net income of 97 cents per share. This comes after two consecutive quarters of exceeding expectations. On average, analysts predict $8.68 billion in revenue this quarter, a rise of 4% from the year-ago quarter. Analysts are forecasting total revenue of $35.34 billion for the year, a rise of 5.1% from last year’s revenue of $33.61 billion.

Bristol-Myers Squibb Co. (NYSE:BMY) will unveil its latest earnings on Thursday, April 26, 2012. The average analyst estimate is for profit of 61 cents per share, a rise of 5.2% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved up from 60 cents. Between one and three months ago, the average estimate moved up. It has dropped from 63 cents during the last month. Analysts are projecting profit to rise by 14% compared to last year’s $1.96.

The company missed estimates last quarter after beating forecasts in the prior two. In the fourth quarter of the last fiscal year, the company reported net income of 53 cents per share versus a mean estimate of profit of 55 cents per share. In the third quarter of the last fiscal year, the company beat estimates by 3 cents. Analysts are projecting a rise of 4.8% in revenue from the year-earlier quarter to $5.25 billion.

Celgene Corporation (NASDAQ:CELG) will unveil its latest earnings on Thursday, April 26, 2012. The average analyst estimate is for net income of $1.02 per share, a rise of 43.7% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved up from 99 cents. Between one and three months ago, the average estimate moved up. It has risen from $1.01 during the last month. Analysts are projecting profit to rise by 25.9% versus last year to $4.32.

The company’s quarterly results have come in above estimates for the last three quarters. Last quarter, the company booked profit of 97 cents per share versus a mean estimate of net income of 95 cents per share. On average, analysts predict $1.32 billion in revenue this quarter, a rise of 18.9% from the year-ago quarter. Analysts are forecasting total revenue of $5.53 billion for the year, a rise of 14.3% from last year’s revenue of $4.84 billion.

Mylan Laboratories, Inc. (NASDAQ:MYL) will unveil its latest earnings on Thursday, April 26, 2012. The average analyst estimate is for profit of 51 cents per share, a rise of 15.9% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved down from 55 cents. Between one and three months ago, the average estimate moved down. It also has dropped from 52 cents during the last month. For the year, analysts are projecting net income of $2.42 per share, a rise of 23.5% from last year.

The company’s quarterly results have come in above estimates for the last three quarters. Last quarter, the company booked profit of 53 cents per share versus a mean estimate of net income of 50 cents per share. Analysts are projecting a rise of 9% in revenue from the year-earlier quarter to $1.58 billion.

 

More from The Cheat Sheet